VYNE Therapeutics (VYNE Therapeutics) GF Value Rank : 1 (As of May. 28, 2024)

View and export this data going back to 2018. Start your Free Trial

What is VYNE Therapeutics GF Value Rank?

VYNE Therapeutics has the GF Value Rank of 1.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of VYNE Therapeutics's GF Value Rank

For the Biotechnology subindustry, VYNE Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VYNE Therapeutics's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where VYNE Therapeutics's GF Value Rank falls into.

VYNE Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of VYNE Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

VYNE Therapeutics (VYNE Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VYNE Therapeutics Inc (NAS:VYNE) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

685 Route 202/206 North, Suite 301, Bridgewater, NJ, USA, 08807

Website

https://www.vynetherapeutics.com

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Executives

Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Mutya Harsch	officer: Chief Legal Officer and GC	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Tyler Zeronda	officer: Interim CFO	C/O VYNE THERAPEUTICS, 520 U.S. HIGHWAY 22, SUITE 204, BRIDGEWATER NJ 08807
Andrew Saik	officer: Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
Rex Bright	director	5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart	officer: Chief Scientific Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski	director, officer: President and CEO	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley	officer: Chief Commercial Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Anthony D Bruno	director	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Hirsch	director	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Ilan Hadar	officer: CFO and Country Manager	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003